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Summary In a retrospective study of the mutational spectrum of the p53 gene in oral squamous cell
carcinoma, 80 primary tumours diagnosed in 1980-90 were included. Using polymerase chain reaction/single
strand conformation polymorphism (PCR/SSCP) analysis 47 mutations were found distributed in 39 of the
tumours (49%). Unexpectedly, the majority of the mutations (29/47; 62%) were found in exon 8, and at
sequencing 17 of them showed a 14 bp deletion in codons 287-292, causing formation of a stop codon and
accordingly a truncated protein lacking the C-terminal. The majority of the patients with the 14 bp deletion
were women (13/17), and it seemed as though certain potential risk factors for carcinoma of the head and neck
were less common in this group.
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The p53 protein, encoded by the tumour-suppressor genep53,
encompasses three distinct regions: (1) the amino-terminus
with a transactivation domain (codons 20-42); (2) the mid-
region with a sequence-specific DNA binding domain (codons
100-293) and (3) the carboxy-terminus with a nuclear
localisation domain (codons 316-325) and an oligomerisa-
tion domain (codons 319- 360) (Greenblatt et al., 1994). In
the mid-region, four of the five evolutionary conserved
domains are found. The wild-type p53 protein acts as a
transcription factor capable of activating transcription of
certain genes such as mdm2 (Momand et al., 1992; Wu et al.,
1993), WAF1/Cipl (El-Deiry et al., 1993; Harper et al., 1993)
and Gadd45 (Carrier et al., 1994). Mdm2 is an oncogene that
exerts negative feedback on p53 (Momand et al., 1992; Wu et
al., 1993), WAF1/Cipl is an inhibitor of cyclin-dependent
kinases (El-Deiry et al., 1993; Harper et al., 1993) and
Gadd45 is capable of blocking progression through the cell
cycle in GI, a process reversible by mdm2 (Levine et al.,
1994). p53 also controls the cell cycle as 'guardian of the
genome' (Lane, 1992), and in UV-damaged skin it is
considered 'guardian of the tissue' (Ziegler et al., 1994)
inducing apoptosis in sunburn cells.
Mutations in the p53 gene are frequent in human cancer,
mostly affecting the conserved parts of the protein. The
importance of p53 mutations in human tumours is, however,
not fully understood. In breast carcinomas, p53 mutation has
been suggested as an important indictaor of short-term
survival (Thorlacius et al., 1993), whereas p53 gene mutations
and deletions so far have not shown any association with
disease progression in squamous cell carcinoma of the head
and neck (SCCHN) (Ahomadegbe et al., 1995).
In SCCHN, mutations in the p53 gene have been found in
around 40-50% of the tumours (Boyle et al., 1993;
Brachman et al., 1992; Brennan et al., 1995; Nylander et
al., 1995).
Codons 238-248 and 278-281 have been pinpointed as
hotspots for these mutations (Field et al., 1993; Sakai and
Tsuchida, 1992; Somers et al., 1992). p53 mutations seem to
be dependent on epidemiological factors, e.g. geographic
origin which in hepatocellular carcinoma has been shown to
be a factor affecting the mutational spectrum of p53
(Greenblatt et al., 1994). The spectrum has also been found
to vary between different countries and races in SCCHN.
Thus, mutations have most frequently been found in exon 7
in the USA, whereas exon 8 was more frequently mutated in
Japan (Field et al., 1993; Sakai and Tsuchida, 1992; Somers
et al., 1992). On the whole, approximately 98% of all p53
mutations in SCCHN are found within exons 5-8 (Green-
blatt et al., 1994). The mutational pattern in SCCHN may
also be influenced by exogenous carcinogens, such as
mutagens in cigarette smoke, e.g. benzo(a)pyrene, that
preferentially induce transversions (G:C-+T:A) (Puisieux et
al., 1991). Furthermore, the spectrum of p53 mutations is
wider in cigarette smokers who also drink alcohol, whereas
p53 mutations in non-smokers/non-drinkers predominate at
CpG sites which are suggested as endogenous mutational
'hotspots' (Brennan et al., 1995).
Mutations in the p53 gene are mainly of missense type,
constituting up to 79-86% of all mutations (Greenblatt et
al., 1994; Levine et al., 1994), whereas only approximately
8% of all mutations found are deletions and insertions
(Levine et al., 1994). In SCCHN deletions have, however,
been found in a higher frequency constituting up to 30% of
all mutations (Brachman et al., 1992; Burns et al., 1993). The
obvious predominance of missense over non-missense
mutations is, however, only seen between codons 130 and
286 (Greenblatt et al., 1994). In an earlier study of p53
mutations in SCCHN we found a deletion of 14 bp in exon 8
in one tumour (Nylander et al., 1995). Big deletions have
been reported in other studies of SCCHN (Ahomadegbe et
al., 1995; Magnusson et al., 1995; Zariwala et al., 1994) as
well as in other tumours, such as colon cancer, breast cancer,
leukaemia and oesophageal carcinoma (Jego et al., 1993;
Huang et al., 1994).
In the present expanded study we investigated the
mutational spectrum of the p53 gene in 80 primary oral
squamous cell carcinomas diagnosed in the period 1980-1990
in the northern part of Sweden. In this paper we report the
finding of a specific 14 bp deletion in exon 8 that we correlated
with epidemiological data collected from these patients.
Materials and methods
Material
Eighty primary oral squamous cell carcinomas diagnosed in
the Departments of Oral Pathology and Pathology in Umea,
Sweden, during the period 1980-90 with representative
formalin-fixed and paraffin-embedded samples were chosen
for the study. The material was limited to tumours located in
the oral cavity, excluding pharyngeal and lip carcinoma.
Control samples consisted of DNA extracted from placenta.
DNA extraction
On paraffin-embedded blocks of oral squamous cell
carcinomas as much normal tissue as possible was scraped
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off with a scalpel. Depending on the size of the tumour, two
to five 10-pm sections were cut from each sample. For each
block a new microtome knife blade was used, and sections
were put in sterile tubes using a tweezer which was washed in
xylol between sectioning of each block. DNA was extracted
according to Shibata (1992). In brief, sections were dewaxed
in a series of xylene and ethanol and dried either at room
temperature or in a speedvac (Savant Speedvac Plus, SC
1lOA). Extraction buffer consisting of 100 mM Tris and 1 mM
EDTA, pH 8.0, was added together with proteinase K at a
concentration of 400 pg ml-'. Samples were incubated
overnight at 37°C, and the following day boiled for 7 min
and centrifuged, after which DNA was found in the
supernatant.
For samples that did not amplify after 2-3 separate PCR
reactions, new sections were cut, and after incubation in xylol
and ethanol the dried pellet was incubated overnight at 37°C
in an extraction buffer consisting of 50 mM Tris, 1 mM
EDTA, 0.5% Tween 20 and 200 pg ml proteinase K
(Wright and Manos, 1990).
Primers
Exons 5-9 of the p53 gene were amplified from each tumour
using primers earlier characterised (Gaidano et al., 1991). All
primers were obtained from Scandinavian Gene Synthesis,
Koping, Sweden.
PCR reaction and SSCP analysis
Each PCR reaction consisted of 1-2 pl of the DNA solution
(DNA content not determined by spectrophotometry), 2.5 pM
dNTPs, 10 pmol of each primer, 1 pCi of [x-32P]dCTP
(Amersham International, Bucks, UK), 1 x Taq polymerase
buffer with 1.5 mM magnesium chloride, and 0.5 U of Taq
polymerase (Boehringer Mannheim, Germany). The total
reaction volume was 10 pl. After a 'hot start' at 94°C for
10 min, 35 cycles with denaturation at 94°C for 30 s,
annealing at 55°C for 1 min and extension at 72°C for
1 min, were performed using a programmable thermal
controller, PTC-100 (MJ Research, Watertown, MA, USA).
The PCR reaction was finished at 72°C for 10 min.
An alternative PCR programme was applied for samples
that had not amplified and were resectioned. In this
programme a 'hot start' at 94°C for 10 min was followed
by 40 cycles with denaturation at 94°C for 1 min, annealing
at 55°C for 1 min and extension at 72°C for 2 min. The last
cycle was followed by a final extension at 72°C for 5 min
(Wright and Manos, 1990). The reason for prolonged times
for denaturation and extension is that amplification from
prepared paraffin-embedded tissue has been found to be less
efficient than amplification of DNA from fresh tissue (Wright
and Manos, 1990).
Reaction mixture (2 pl) was diluted with 50 pl 0.1%
sodium dodecyl sulphate (SDS)/10 mM EDTA and 52 pl 98%
formamide, 0.05% bromophenol blue, 0.05% xylene cyanol
and 20 mM sodium hydroxide. This mixture was heated at
95°C for 5 min and chilled on ice, then 3 pl was loaded in
each lane of a 6% polyacrylamide/TBE gel with 10%
glycerol. Gels were run at room temperature at 3 W for
16-20 h, and autoradiography was performed at -70°C for
4-48 h.
Cloning and sequencing of PCR products
After the initial PCR/SSCP analysis of all tumours was
finished a new non-radioactive PCR reaction was performed
for tumours to be sequenced. This reaction amplifying the
mutated exon was performed as described above with a
higher concentration of dNTPs (200 pM) and a total volume
of 50 pl. For ligation and cloning of the PCR product, a
pGEM-T Vector System (Promega) was used, with a 1:1
molar ratio of insert-vector.
At least 16 and at most 48 different clones from each
tumour were first analysed by PCR/SSCP, and then a
minimum of two clones, showing the same mutation as was
found in the initial PCR/SSCP analysis, were sequenced.
Following plasmid preparation dideoxy sequencing of both
strands was performed.
PCR control reactions
For tumours with mutation in exon 8 three different control
PCR reactions were performed. The first reaction used new
primers upstream and downstream of the initial primer pair.
Primers used were: 5'CTGCCTCTTGCTTCTCTTTTC and
3'TGGTGTTGTTGGGCAGTG (Scandinavian Gene Synth-
esis). The PCR programme was the same as the one used
before, except for an annealing temperature of 56°C. PCR
products were pretreated and run on a gel as described earlier.
For the second control reaction new sections were cut from
the paraffin blocks, and a new set of the same primers as was
initially used for exon 8 was purchased as well as a new dNTP
mixture and new Taq polymerase. The PCR products were
analysed on a 6% polyacrylamide/TBE gel as described earlier.
All steps from sectioning, DNA extraction to mixing of the
PCR reaction were performed in another laboratory, which
was not involved in our earlier p53 analysis.
To exclude the possibility of contamination of tumour
samples by vector-ligated exon 8-specific DNA, a third
control reaction was performed. In this non-radioactive
PCR reaction comprising 30 cycles with denaturation at
940C for 1 min, annealing at 560C for 1 min and extension at
720C for 2 min, primers specific for the pGEM-t vector, SP6
and T7 (Promega) were applied. The reaction volume
consisted of 50 pl with 10 pl of DNA extract.
Immunohistochemistry
For the immunohistochemical analysis of p53 protein a
monoclonal antibody, D07 (Novocastra Laboratories, New-
castle, UK), recognising a denaturation-resistant epitope
between amino acids 1 and 45 was applied (Vojtesek et al.,
1992).
Results
p53 mutation analysis using PCR and SSCP
Amplification of exon 5-8 was accomplished in 89-96% of
the tumours, and of exon 9 in 60% ofthe tumours. A total of
47 mutations were found distributed in 39 tumours, as eight
of these had two mutations in different exons. All tumours
with two mutations were, with one exception, located either
in the tongue or the floor of the mouth.
The majority of the mutations (29 out of 47; 62%) were
found in exon 8, and many of those showed a concordant
pattern in the SSCP analysis (Figure 1). The remaining 18
mutations were almost equally distributed between exons 5
(seven), 6 (four) and 7 (seven). No mutations were found in
exon 9.
Sequencing of mutations in exon 8
The predominance of mutations in exon 8 was unexpected
and made us investigate these tumours further, first by
cloning and sequencing and then by different control PCR
reactions. The majority of the sequenced tumours (17/29;
59%) showed a specific deletion of 14 bp in codons 287-292.
This deletion caused a frameshift, formation of a stop codon
near the end of the exon and accordingly a truncated protein.
The same 14 bp deletion was also found in two other
tumours, but only in a single clone among 32-48 clones that
were scanned. These two tumours were only considered
mutation positive in the SSCP analysis and not in the
sequence analysis and were therefore not included in further
analysis. Five of the eight tumours with two mutations had
the 14 bp deletion plus a mutation in either exon 5, 6 or 7.For details of the mutations in exon 8 see Table I and Figure
2.
PCR control reactions
For control reactions, a new set of primers external to the
initial primer set was first applied, giving PCR products of up
to 281 bp in length. In the following SSCP analysis no
consistent difference in band pattern could be seen between
tumour samples and normal control samples from placenta.
The SSCP pattern for tumours with the 14 bp deletion was
14 bp del., codons 287-292
A-* G, codon 286
12 3 4 5
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consistent, whereas two variable band patterns for the normal
control samples were found, one of these concordant with the
pattern for the 14 bp deletion. Out of the three tumours with
a point mutation (C--T) in different codons mutation could
be detected in one case due to aberrant band pattern, whereas
the other two tumours showed no aberration. A reduction in
mutation-induced mobility change is often found when the
amplified product exceeds 180 bp (Moyret et al., 1994). This
could explain the difficulty we had in differentiating between
these new products being up to 281 bp in length.
Amplification of these long fragments could not be achieved
in all tumours, possibly owing to the formaldehyde fixation
(Karlsen et al., 1994).
In another control series all steps from sectioning and
DNA extraction to mixing new reactions with fresh
ingredients were performed in another laboratory, giving
the same pattern on SSCP gels as found in the initial analysis
(Figure 3). PCR products from tumours with the 14 bp
deletion gave two distinct bands on agarose gel compared
with one band for normal samples and samples with other
mutations (Figure 4).
Additional samples taken at the same time as the initial
biopsy were available from five patients. When analysing








262 270 276 282 286
269-270 287----292
Figure 1 Initial PCR/SSCP analysis of exon 8 of the p53 gene.
Lane 1, non-mutated tumour; lane 2, tumour with a transversion
A-+G, codon 286 (tumour 15 in Table I); lane 3, tumour with
14bp deletion, codons 287-292 (tumour 16 in Table I); lane 4,
non-mutated tumour; lane 5, tumour with 14bp deletion, codons
287-292 (tumour 17 in Table I).
Figure 2 Distribution of29 mutations in 27 tumours within exon
8. Each dot represents one mutation. Exact localisation of point
mutations is given in the first row under the exon line and length
of deletions in the second row. The 17 tumours with 14bp
deletion between codons 287-292 constitute group A in the
statistical comparison with all other tumours (group B).
Table I Tumour localisation, sequence of p53 mutation and results from immunohistochemical analysis (IHC) for all tumours with mutation
in exon 8.
No. Localisation Sequence IHC Smoker Mutation in other exon
1 Tongue Deletion 14 bp, codon 287-292 Pos.
2 Gingiva Deletion 14 bp, codon 287-292 Pos.
3 Tongue Deletion 14 bp, codon 287-292 Neg. - Exon 7
4 Floor of mouth Deletion 14 bp, codon 287-292 Pos. -
5 Floor of mouth Deletion 14 bp, codon 287-292 Pos. *
6 Floor of mouth Deletion 14 bp, codon 287-292 Neg. -
7 Floor of mouth Deletion 4 bp, codon 269-270 Pos. + Exon 7
8 Gingiva Deletion 14 bp, codon 287-292 Neg. + Exon 6
9 Tongue Deletion 14 bp, codon 287-292 Pos. +
10 Tongue Deletion 14 bp, codon 287-292 Pos. - Exon 6
11 Gingiva Deletion 14 bp, codon 287-292 Neg. *
12 Floor of mouth C--T, codon 282 Pos. -
13 Gingiva Deletion 14 bp, codon 287-292 Pos.
14 Gingiva Deletion 14 bp, codon 287-292; A--+G, Neg. ?
codon 304
15 Floor of mouth A-+G, codon 286 Neg. +
16 Bucca Deletion 14 bp, codon 287-292 Pos.
17 Floor of mouth Deletion 14 bp, codon 287-292 Neg. - Exon 7
18 Floor of mouth Deletion 14 bp, codon 287-292; A-.G, Neg.
codon 304
19 Floor of mouth C-+T, codon 306 Neg.
20 Floor of mouth Deletion 14 bp, codon 287-292 Pos. - Exon 5
21 Floor of mouth C-)T, codon 276 Pos.
22 Floor of mouth Deletion 14 bp, codon 287-292 Pos. ?
23 Gingiva C-.T, codon 306 Neg. +
24 Floor of mouth T-+G, codon 270 Neg. +
25 Tongue T-+G, codon 270 Pos. - Exon 5
26 Gingiva C-+T, codon 282 Pos. +
27 Floor of mouth C-VT, codon 282 Pos.
*Owing to technical difficulties only one of two clones from tumours 20 and 22 could be successfully sequenced. Non-smokers who stopped
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patient a precancerous lesion taken from the same location as
the biopsy later diagnosed as carcinoma, most probably from
the border area, was also analysed, showing a mutation in
exon 8.
The third PCR control reaction with vector specific
primers showed no product in any tumour sample tested,
whereas products were seen in control samples consisting of
amplified exon 7-specific DNA from the p53 gene inserted
into a pGEM-T vector (Figure 5).




+ transition A -G
x x x Since all patients were included in an epidemiological case -
control study, data on demographics and exposure conditions
collected by questionnaires were available. Tumours were
divided into two groups: group A including tumours with the
14 bp deletion (17 patients) and group B including all other
tumours (63 patients). Five patients, however, had refused to
answer the questionnaire and the groups were therefore
reduced to 15 and 60 patients respectively.
There was a statistically significant overrepresentation of
women in group A (80%) compared with group B (47%).
The majority of patients in group A (60%) were over 70
years at diagnosis compared with only 47% in group B.
Patients in group A also showed significantly lower exposure
to different chemical agents as well as a lower rate of tobacco
smoking. The predominance of women in this group could,
Figure 3 PCR/SSCP control of exon 8 for tumours with a 14bp
deletion in codons 287-292 confirmed by sequencing. All steps in
this control PCR reaction were performed in another laboratory,
and new sections as well as new ingredients were used. Lane 1,
tumour with the 14bp deletion and a transition A- G, codon 304
(tumour 14 in Table I). The presence of two mutations in this
tumour explains why the lowest band is not co-localised with the
corresponding band in the other tumours with the 14bp deletion;
lane 2, tumour with the 14bp deletion (tumour 4 in Table I); lane
3, new sections from the same tumour as in lane 2, showing the
same pattern with somewhat weaker aberrant bands. This is
explained by the fact that this part of the sample contained less
tumour tissue; lane 4, tumour with the 14bp deletion (tumour 17
in Table I). The initial analysis of the same tumour is shown in
lane 5 in Figure 1; lane 5, normal placenta sample.
Figure 4 Products from a non-radioactive PCR from three
different tumours run on a 4% agarose gel. Lane 1, tumour with
the 14bp deletion showing two bands (tumour 4 in Table I); lane
2, tumour without the 14bp deletion showing only one band; lane
3, tumour with the 14bp deletion showing two bands (tumour 3
in Table I).
Figure 5 A non-radioactive PCR reaction with vector specific
primers, SP6 and T7. Lane 1, size marker + x 174; lane 3 and 4,
positive controls consisting of amplified exon 7-specific DNA
ligated into a pGEM-T vector; lane 5, negative control; lane 6
and 7, non-mutated tumours; lane 8, tumour with a transversion
A-.G, codon 286 (tumour 15 in Table I); lane 9-13, tumours
with the 14bp deletion, codons 287-292; lane 15, size marker
pGEM.
Table II Occurrence (%) of different factors in group A (with the
14 bp deletion) and group B (all other tumours), and P-values based
on chi-square test according to Pearson for the difference between
the groups
Group A Group B
(n = 15) (n =60) P-value
Demographic factors
Female 80.0 46.7 0.02
Dead at latest follow-up 80.0 60.0 0.15
Age over 70 at diagnosis 60.0 46.7 0.36
Exposure factors
Chemical agents at work 0.0 38.3 0.004
Organic solvents 0.0 18.3 0.073
Pesticides 0.0 13.3 0.13
Tobacco smoking 33.3 55.0 0.13
Dental radiograph 38.5 66.0 0.07
Gold fillings 11.1 36.7 0.13
Amalgam fillings 36.4 72.5 0.02
Number of patients 15 60
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however, be a confounding factor when considering these
exposures. Other investigated exposure factors, with as yet
unknown impact on the risk for SCCHN that differed
between the groups were dental radiograph and gold and
amalgam fillings (Table II).
The P-value for differences between group A and B was
calculated using the chi-square test according to Pearson.
DiscnwWn
The aim of the present study was to investigate the
mutational spectrum in the p53 gene in a group of oral
squamous cell carcinoma. The predominance of mutations in
exon 8 was an unexpected finding. Predominance of
mutations in one exon is consistent with earlier results
where a geographically based overrepresentation of p53
mutations in different exons has been found (Field et al.,
1993; Sakai and Tsuchida, 1992; Somers et al., 1992). Almost
two-thirds (63%) of the mutations found in exon 8 were
deletions of 14 bp in codons 287-292. Big deletions
occurring in the p53 gene have been reported previously
(Ahomadegbe et al., 1995; Huang et al., 1994), but not to
such an extent as in this material, constituting over a third of
all mutations found. These deletions were located outside the
five highly conserved regions between codons 13-280. For
SCCHN codons 287-292 is not a previously known hotspot
area for mutations, but in a study of oesophageal tumours
(Huang et al., 1993) a deletion of 5 bp in the same area has
been reported.
When using a sensitive method like PCR, the question of
contamination as an explanation for the finding of a novel
deletion naturally arises. However, in the present study
extraordinary care was taken throughout the entire work to
avoid any possibility of contamination. At sectioning a
much more careful method than generally recommended
(Shibata, 1992) was applied, and in the control PCR
reaction performed in an outside laboratory only fresh
ingredients (including primers) were used. Furthermore, no
amplifying or cloning of the exon 8-specific DNA was
performed until all tumours had been analysed by PCR/
SSCP, avoiding any possibility of contamination of tumour
samples or PCR ingredients. Control of tumour samples for
vector contamination also gave a negative result. Some
blocks were also resectioned at a later time point showing
concordant results in the analysis. In this control reaction all
ingredients were new, and all steps performed in a
laboratory not before used for PCR analysis or cloning.
The non-existence of the same 14 bp deletion in samples
from ulcerative colitis and colon carcinoma run at the same
time using the same equipment and ingredients furthermore
contradicts any possible contamination and confirms the
true nature of this novel deletion in oral squamous cell
carcinoma.
One explanation for the 14 bp deletion could be the close
proximity of three GA dinucleotides in the area, one located
just outside the deletion and the other two at each end of the
deletion. This might cause erroneous reannealing between the
first repeat and the complementary strand of the third repeat
when the DNA chain opened before replication (Jego et al.,
1993). Thus, a loop consisting of the two other GA
dinucleotides and the sequence in between was formed and
excised before actual replication occurred.
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